Conclusions: PFO closure may resolve symptomatic postural dyspnea and hypoxemia and is an effective method for treating OPS.
Okayama University Hospital, Okayama, Japan, 2 Okayama University, Okayama, Japan, 3 Okayama University, Okayama, Japan Background: Recently revised instructions for use suggested that patients with inferior vena cava (IVC) rim deficiency should be considered as contraindication of transcatheter closure of atrial septal defect because of risk of cardiac erosion. Conventional balloon sizing technique may produce the over sizing of device selection in this anatomical condition. However, concern still remains the relationship between IVC rim deficiency and complications. Methods: Methods: From 2007 through 2013, 476 consecutive patients with ASD were performed transcatheter ASD closure using Amplatzer Septal Occluder. Patients were divided into 2 groups (with or without IVC rim deficiency) using transesophageal echocardiographic evaluation. ASD diameter, selected device size, procedure success rate, complications (device migration, erosion) were evaluated. In patients with IVC rim deficiency, 3-4 mm larger sized device was selected without balloon sizing technique. Contrary, balloon sizing technique was used for device selection in patients without IVC rim deficiency.
Results: Patients with IVC rim deficiency had significantly larger defect size and increased Qp/Qs ratio compared to patients without IVC rim deficiency. Although patients with IVC rim deficiency had significantly lower procedure success rate, more than 90% patients with IVC deficiency could be treated with low complication rate such as device migration or cardiac erosion. (Table) Conclusions: Under the appropriate device selection and device deployment technique, majority of patients with IVC rim deficiency can be treated by transcatheter closure with low complication rate.
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Paradoxical embolic myocardial infarction Background: Despite several negative prospective randomized trials on the efficacy of patent foramen ovale (PFO) occlusions the discussion on the validity of these studies and on new indications is ongoing. We investigated the risk of paradoxical embolic myocardial infarction over a time period of more than 13 years. Methods: Our effort to describe the epidemiology of paradoxical embolic myocardial infarction included a retrospective and a prospective approach: We analyzed retrospectively the incidence of paradoxical coronary embolism over 10 years and then prospectively undertook the effort to prove this using the same methodology over 39 months in another center. All patients with acute myocardial infarction (AMI) according to ECG criteria and elevation of cardiac troponin or creatin kinase and normal coronary arteries were screened for PFO and if no other reasons for the AMI could be found after thorough work-up, were judged as presumed paradoxical embolism. Results: In a retrospective analysis over 10 years amongst 4848 AMIs 22 patients (0.45 %) were identified to have had presumed paradoxical embolic pathogenesis based on strict criteria of absence of arrhythmias and virtual absence of atherosclerosis in any vascular territory. To further elucidate the epidemiologic size of this disease entity we prospectively studied 1654 AMIs in another tertiary referral center over a time period of 39 months and found an incidence of 13 presumed paradoxical embolic AMIs (0.79 %) based on application of the same criteria. The patients in the paradoxical embolic cohorts were younger (45.7 AE 11.5 years) as compared to the overall AMI population (65.0 AE 13.2 years), most likely based on the criteria applied (exclusion of detectable atherosclerosis). Conclusions: Paradoxcial embolism through a PFO is the most likely cause of AMI in roughly 5/1000 patients. While this is a rather low rate, the incidence is still high enough to warrent clinical attention. 
